Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3751
Custom Truck One Source
CTOS
$2.23B
| $541K | ﹤0.01% |
93,975
+9,070
| +11% | +$55.4K |
2022 Q1
15 quarters
|
|
3752
Alto Neuroscience
ANRO
$973M
| $541K | ﹤0.01% |
30,392
+30,350
| +72,262% | +$382K |
2024 Q1
7 quarters
|
|
3753
Entravision Communication
EVC
$681M
| $540K | ﹤0.01% |
184,463
+13,814
| +8% | +$35.9K |
2016 Q1
39 quarters
|
|
3754
Greif Class B
GEF.B
$4.08B
| $540K | ﹤0.01% |
7,231
+685
| +10% | +$45.5K |
2016 Q3
37 quarters
|
|
3755
Beyond Meat
BYND
$142M
| $539K | ﹤0.01% |
21,908
+11,813
| +117% | +$493K |
2019 Q2
26 quarters
|
|
|
BMNR
3756
BitMine Immersion Technologies
BMNR
$15.8B
| $538K | ﹤0.01% |
19,822
-89,956
| -82% | -$3.65M |
2025 Q3
1 quarter
|
|
3757
Rocket Pharmaceuticals
RCKT
$281M
| $537K | ﹤0.01% |
153,049
+3,656
| +2% | +$12.5K |
2019 Q1
27 quarters
|
|
3758
Owlet
OWLT
$148M
| $537K | ﹤0.01% |
33,180
+30,777
| +1,281% | +$349K |
2025 Q2
2 quarters
|
|
3759
CALL
Corteva
CTVA
$7.95B
| $536K | ﹤0.01% |
8,000
+4,000
| +100% | +$259K |
2025 Q2
2 quarters
|
|
3760
Ginkgo Bioworks
DNA
$832M
| $536K | ﹤0.01% |
64,465
+6,665
| +12% | +$71.8K |
2022 Q1
15 quarters
|
|
3761
Fractyl Health
GUTS
$64.7M
| $535K | ﹤0.01% |
+243,294
| New | +$392K |
2025 Q4
0 quarters
|
|
3762
PUT
ASP Isotopes
ASPI
$446M
| $535K | ﹤0.01% |
100,000
| – | – |
2025 Q2
2 quarters
|
|
3763
Babcock & Wilcox
BW
$849M
| $533K | ﹤0.01% |
84,118
+84,017
| +83,185% | +$414K |
2022 Q1
15 quarters
|
|
3764
NewtekOne
NEWT
$323M
| $531K | ﹤0.01% |
46,818
+3,638
| +8% | +$39.7K |
2023 Q2
10 quarters
|
|
3765
B&G Foods
BGS
$219M
| $531K | ﹤0.01% |
123,460
+6,451
| +6% | +$28.8K |
2013 Q2
50 quarters
|
|
3766
MainStreet Bancshares
MNSB
$178M
| $530K | ﹤0.01% |
26,048
+3,707
| +17% | +$72.5K |
2023 Q2
10 quarters
|
|
3767
BV Financial
BVFL
$180M
| $530K | ﹤0.01% |
29,203
+781
| +3% | +$13.4K |
2024 Q3
5 quarters
|
|
3768
E.W. Scripps
SSP
$254M
| $529K | ﹤0.01% |
132,533
-48,415
| -27% | -$163K |
2016 Q1
39 quarters
|
|
3769
Lightbridge
LTBR
$225M
| $528K | ﹤0.01% |
41,791
+11,549
| +38% | +$222K |
2024 Q4
4 quarters
|
|
3770
Stoneridge
SRI
$192M
| $528K | ﹤0.01% |
91,207
+34,905
| +62% | +$220K |
2013 Q2
50 quarters
|
|
3771
ArcelorMittal
MT
$48.5B
| $526K | ﹤0.01% |
11,542
+11,365
| +6,421% | +$467K |
2025 Q3
1 quarter
|
|
3772
Orion
OEC
$327M
| $526K | ﹤0.01% |
99,612
+13,858
| +16% | +$75.2K |
2018 Q2
30 quarters
|
|
3773
CALL
Genius Sports
GENI
$1.61B
| $525K | ﹤0.01% |
+47,600
| New | +$519K |
2025 Q4
0 quarters
|
|
3774
Abeona Therapeutics
ABEO
$288M
| $523K | ﹤0.01% |
99,311
+37,014
| +59% | +$186K |
2022 Q3
13 quarters
|
|
3775
Woodside Energy
WDS
$41.4B
| $522K | ﹤0.01% |
+33,456
| New | +$532K |
2025 Q4
0 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.